Regeneron Pharmaceuticals, Inc.
REGN
$828.42
$3.940.48%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | 13.30B | 12.92B | 12.56B | 12.58B | 12.65B |
Total Other Revenue | 548.10M | 572.20M | 537.00M | 536.10M | 451.30M |
Total Revenue | 13.85B | 13.49B | 13.10B | 13.12B | 13.10B |
Cost of Revenue | 5.74B | 5.49B | 5.40B | 5.28B | 5.17B |
Gross Profit | 8.11B | 8.00B | 7.70B | 7.84B | 7.93B |
SG&A Expenses | 2.90B | 2.83B | 2.72B | 2.63B | 2.55B |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | 37.40M | 28.90M | 13.70M | -2.10M | -8.20M |
Total Operating Expenses | 9.76B | 9.42B | 9.11B | 8.88B | 8.69B |
Operating Income | 4.09B | 4.07B | 3.99B | 4.23B | 4.41B |
Income Before Tax | 4.97B | 4.59B | 4.04B | 4.20B | 4.38B |
Income Tax Expenses | 314.90M | 265.50M | 184.20M | 245.70M | 385.30M |
Earnings from Continuing Operations | 4.65K | 4.32K | 3.86K | 3.95K | 3.99K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 4.65B | 4.32B | 3.86B | 3.95B | 3.99B |
EBIT | 4.09B | 4.07B | 3.99B | 4.23B | 4.41B |
EBITDA | 4.56B | 4.52B | 4.42B | 4.65B | 4.82B |
EPS Basic | 43.23 | 40.31 | 36.11 | 37.05 | 37.36 |
Normalized Basic EPS | 27.35 | 27.05 | 26.28 | 27.24 | 28.12 |
EPS Diluted | 40.41 | 37.76 | 33.85 | 34.75 | 35.05 |
Normalized Diluted EPS | 25.57 | 25.35 | 24.64 | 25.56 | 26.40 |
Average Basic Shares Outstanding | 430.60M | 428.80M | 427.70M | 427.00M | 427.40M |
Average Diluted Shares Outstanding | 460.50M | 457.70M | 456.20M | 455.10M | 455.30M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |